uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants
Baylor Coll Med, Dept Pediat Hematol Oncol, Houston, TX 77030 USA.
Univ Chicago, Sect Hematol Oncol, Chicago, IL 60637 USA;Univ Chicago, Ctr Clin Canc Genet, Chicago, IL 60637 USA.
Univ N Carolina, Sch Med, Dept Genet, Chapel Hill, NC 27515 USA.
Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA.
Show others and affiliations
2019 (English)In: BLOOD ADVANCES, ISSN 2473-9529, Vol. 3, no 20, p. 2962-2979Article in journal (Refereed) Published
Abstract [en]

Standardized variant curation is essential for clinical care recommendations for patients with inherited disorders. Clinical Genome Resource (ClinGen) variant curation expert panels are developing disease-associated gene specifications using the 2015 American College of Medical Genetics and Genomics (ACMG) and Association for Molecular Pathology (AMP) guidelines to reduce curation discrepancies. The ClinGen Myeloid Malignancy Variant Curation Expert Panel (MM-VCEP) was created collaboratively between the American Society of Hematology and ClinGen to perform gene- and disease-specific modifications for inherited myeloid malignancies. The MM-VCEP began optimizing ACMG/AMP rules for RUNX1 because many germline variants have been described in patients with familial platelet disorder with a predisposition to acute myeloid leukemia, characterized by thrombocytopenia, platelet functional/ultrastructural defects, and a predisposition to hematologic malignancies. The 28 ACMG/AMP codes were tailored for RUNX1 variants by modifying gene/disease specifications, incorporating strength adjustments of existing rules, or both. Key specifications included calculation of minor allele frequency thresholds, formulating a semi-quantitative approach to counting multiple independent variant occurrences, identifying functional domains and mutational hotspots, establishing functional assay thresholds, and characterizing phenotype-specific guidelines. Preliminary rules were tested by using a pilot set of 52 variants; among these, 50 were previously classified as benign/likely benign, pathogenic/likely pathogenic, variant of unknown significance (VUS), or conflicting interpretations (CONF) in ClinVar. The application of RUNX1-specific criteria resulted in a reduction in CONF and VUS variants by 33%, emphasizing the benefit of gene-specific criteria and sharing internal laboratory data.

Place, publisher, year, edition, pages
AMER SOC HEMATOLOGY , 2019. Vol. 3, no 20, p. 2962-2979
National Category
Hematology
Identifiers
URN: urn:nbn:se:uu:diva-397043DOI: 10.1182/bloodadvances.2019000644ISI: 000492438500005PubMedID: 31648317OAI: oai:DiVA.org:uu-397043DiVA, id: diva2:1371232
Available from: 2019-11-19 Created: 2019-11-19 Last updated: 2019-11-19Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records BETA

Baliakas, Panagiotis

Search in DiVA

By author/editor
Baliakas, Panagiotis
By organisation
Science for Life Laboratory, SciLifeLabExperimental and Clinical Oncology
Hematology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 7 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf